Overview

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Sometimes the transplanted cells are rejected by the body's normal tissues. Antithymocyte globulin may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus biological therapy followed by peripheral stem cell transplantation in treating patients who have hematologic cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Chicago
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antilymphocyte Serum
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Criteria
DISEASE CHARACTERISTICS: Histologically proven hematologic malignancy for which there is no
standard curative therapy, including, but not limited to: Low grade non-Hodgkin's lymphoma
(NHL) Mantle cell lymphoma Chronic lymphocytic leukemia (stage II-IV) Myelodysplastic
syndrome, including: Refractory anemia (RA) with ringed sideroblasts RA with excess blasts
(RAEB) RAEB in transformation Chronic myelomonocytic leukemia Multiple myeloma OR
Histologically proven hematologic malignancy that has failed 1 prior therapy OR is at high
risk for relapse, including, but not limited to: Intermediate grade NHL High grade NHL
Hodgkin's disease Acute lymphoblastic lymphoma Acute myelogenous leukemia OR Histologically
proven chronic myelogenous leukemia in chronic or accelerated phase, with the following
risk factors that preclude eligibility for standard allogeneic peripheral blood stem cell
transplantation: Older age Poor performance status Healthy, partially related HLA 5/6 or
6/6 serologic match donor available A new classification scheme for adult non-Hodgkin's
lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma
will replace the former terminology of "low", "intermediate", or "high" grade lymphoma.
However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS: Age: 18 to 60 or physiologic 70 Performance status: Karnofsky 0-2
Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than
2.0 mg/dL SGOT and SGPT less than 2 times normal No active hepatitis Renal: Creatinine less
than 2.0 mg/dL OR Creatinine clearance greater than 50 mL/min Cardiovascular: Ejection
fraction greater than 45% OR Cardiac clearance Pulmonary: DLCO at least 50% predicted
Other: No active infection HIV-1, HIV-2, and HTLV-1 negative Not pregnant or nursing

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
specified